Newswise — Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery—the ...

CLEVELAND, Ohio — A genomic test used to assess prostate cancer risk may also help doctors determine which patients are ...

A national study of more than 20,000 men with localized prostate cancer found that surgery was linked to higher rates of urinary incontinence and erectile dysfunction, while radiation therapy was ...

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

A prospective study of 24 men found that 18F-Flotufolastat PSMA PET MRI detected recurrent prostate cancer in 25 percent of ...